课题基金 / 基金详情

Carcinoma cell radiosensitization by MAPK inhibition

Carcinoma cell radiosensitization by MAPK inhibition
MAPK 抑制对癌细胞放射增敏
批准号:
6773256
负责人:
PAUL DENT
金额:
$19.58万
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-08-01 至 2007-07-31

项目摘要

项目成果

PAUL DENT的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The central goal of this application is to develop a rational mechanistic basis for employing agents that disrupt the mitogen activated protein kinase (MAPK) signal transduction pathway in order to potentiate the anti-tumor activity of ionizing radiation. This strategy is based upon recent evidence indicating that specific inhibitors of the MAPK pathway interact synergistically with radiation to initiate the apoptotic protease cascade. Our underlying hypothesis is that inhibition of MAPK, an enzyme implicated in G2/M progression, leads to a potentiation of radiation-mediated cell death. We postulate that this phenomenon stems from, or is profoundly influenced by, perturbations in cell cycle regulation, a diminished threshold for tolerating mitochondria) dysfunction, and a reduced ability to survive radiation-induced DNA damage. We have shown in human carcinoma cells that are autocrine regulated via an ErbB 1 and TGFalpha interaction, survive irradiation in a MAPK- dependent fashion. Radiation causes activation of the MAPK pathway and blunting of MAPK activation enhanced the proportion of cells found in G2/M phase 24h after irradiation, which was associated with increased apoptosis. In this proposal we will examine how the MAPK signaling pathway is responsible for cell cycle control, caspase regulation and survival, with measurements of apoptosis and cell cycle regulatory protein expression in carcinoma cells. In Aims 1 and 2 we will test the hypothesis that MAPK inhibition enhances radiation-induced cell killing by potentiating the activation of caspases 8, 9 and 3. In Aim 3 we will test the hypothesis that reduced MAPK activity modifies the radiation / ATM / cdc 2 interaction, altering cell cycle progression leading to enhanced apoptosis. We propose that MAPK signaling is an essential survival factor in the response of the cell to DNA damage. Collectively, these studies will determine the molecular mechanisms by which inhibition of MAPK enhances apoptosis and radio-sensitivity.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
Sequence Dependent Exposure of Mammary Carcinoma Cells to Taxotere® and the MEK1/2 Inhibitor U0126 Causes Enhanced Cell Killing In Vitro
乳腺癌细胞序列依赖性暴露于 Taxotere® 和 MEK1/2 抑制剂 U0126 导致体外细胞杀伤增强
DOI: --
发表时间: 2003
期刊: Cancer Biology & Therapy
影响因子: 3.6
作者: [A. Yacoub, S. Han, R. Carón, D. Gilfor, S. Mooberry, S. Grant, P. Dent]
通讯作者: P. Dent
Pemetrexed and sildenafil for lung cancer
OSU-03012 therapy for glioblastoma
Lapatinib and Obatoclax combination therapy
Lapatinib and Obatoclax combination therapy
国内基金
海外基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2020
  • 负责人:
    郑绪阳
  • 依托单位:
去乙酰化酶SIRT1在前体mRNA可变剪切中的作用及其生理病理效应研究
  • 批准号:
    31970691
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2019
  • 负责人:
    张胜萍
  • 依托单位:
TM9SF4调控非小细胞肺癌细胞凋亡机制研究
  • 批准号:
    31900527
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2019
  • 负责人:
    孙磊
  • 依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2017
  • 负责人:
    卫高菲
  • 依托单位: